Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics
ZYNE Price/Volume Stats
| Current price | $1.30 | 52-week high | $1.40 |
| Prev. close | $1.27 | 52-week low | $0.25 |
| Day low | $1.26 | Volume | 862,700 |
| Day high | $1.34 | Avg. volume | 515,333 |
| 50-day MA | $1.14 | Dividend yield | N/A |
| 200-day MA | $0.61 | Market Cap | 70.12M |
ZYNE Stock Price Chart Interactive Chart >
Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio
Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.
Latest ZYNE News From Around the Web
Below are the latest news stories about ZYNERBA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsDEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “Offer”) by Harmony Biosciences Holdings, Inc. (“Harmony”) and its wholly owned subsidiary, Xylophone Acquisition Corp. (“Purchaser”), to purchase all outstan |
20 Countries With Highest Rate of EpilepsyIn this article, we will take a detailed look at the 20 countries with the highest rates of epilepsy with insights into number of epilepsy cases by country and population. For a quick overview of 5 countries with high epilepsy rates, read our article 5 Countries with Highest Rate of Epilepsy. Epilepsy is a common neurological disorder […] |
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We urge you to promptly tender your shares in response to the pending tender offer (the “Offer") by |
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq: ZYNE) to 5:00 p.m., New York City time, on Tuesday, October 10, 2023, unless further extended. The tender offer was previously s |
Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncOn September 13, 2023, President Terri Sebree of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) sold 12,401 shares of the company's stock. |
ZYNE Price Returns
| 1-mo | N/A |
| 3-mo | -1.52% |
| 6-mo | 272.49% |
| 1-year | 117.03% |
| 3-year | -70.59% |
| 5-year | -72.92% |
| YTD | 145.28% |
| 2022 | -81.60% |
| 2021 | -12.73% |
| 2020 | -45.36% |
| 2019 | 103.37% |
| 2018 | -76.28% |
Continue Researching ZYNE
Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...